Evaluating Automated Versus Manual Oxygen Control During High Flow Nasal Oxygen Therapy in Adults with Acute Respiratory Failure in the Emergency Room

What this Trial Is About

Researchers are evaluating a new oxygen delivery method called closed-loop oxygen control during high flow nasal oxygen therapy HFNO for adults with acute respiratory failure in emergency room settings. HFNO supports breathing by delivering humidified oxygen through a nasal interface, but current oxygen levels are manually adjusted, often leading to oxygen saturation levels outside the desired range. The study aims to see if automated oxygen control improves time spent within the target oxygen saturation range compared to manual adjustment. The trial compares two 6-hour periods of oxygen delivery in a randomized crossover design. In one period, oxygen levels FiO2 are automatically adjusted by a closed-loop controller based on continuous oxygen saturation SpO2 monitoring, maintaining target SpO2 levels set by clinicians. In the other period, oxygen is manually adjusted by clinicians based on SpO2 readings. This device-based approach is designed to quickly respond to changes in oxygen needs and avoid excessive oxygen exposure. Participants admitted to the emergency room who require HFNO with FiO2 of at least 30% will be involved. Researchers will monitor oxygen saturation continuously and record the percentage of time spent within the optimal SpO2 range over 6 hours. Secondary measures include time with SpO2 below or above target ranges, oxygen usage, and event counts of oxygen desaturation. Safety monitoring includes quality of SpO2 signals and clinical status. The study will assess whether automated control can improve oxygen management during critical care treatment.

Closed-Loop O2 Use During High Flow Oxygen Treatment of Critical Care Adult Patients (CLOUDHFOT)